ERBB2 and breast cancer: Thus, since the majority of the analyzed PET-based features that were associated with response to NAC occurred among BC HER2-negative tumors, our findings can reflect the known higher probability of TN BC to achieve pCR in comparison with luminal B-like subtype with no HER2 amplification [38].